Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond

Table 8 Results of immune checkpoint inhibitors and combination therapy

	Nivolumab[58]	Pembrolizumab[59]	Pembrolizumab plus Lenvatinib[67]	Atezolizumab plus Bevacizumab1[62]	SHR-1210 plus Apatinib[64]	Durvalumab plus Tremelimumab[65]
	(n = 214)	(n = 104)	(n = 26)	(n = 73)	(n = 18)	(n = 40)
ORR (%, 95%CI)	20 (15-26)2	17 (11-26)2	42.3 (23.4-63.1)3	343	38.9 3	252
DCR (%, 95%CI)	64 (58-71)	62 (52-71)	100	75	83.3	57.5 (> 16 wk)
PFS (M, 95%CI)	4.0 (2.9-5.4)	4.9 (3.4-7.2)	9.7 (5.6-NE)	7.5 (0.4-23.9)	7.2 (2.6-NE)	NA
OS (M, 95%CI)	NR (9M, 74%)	12.9 (9.7-15.5)	NR	NR	NR	NA
DOR (M)	9.9 (8.3-NE)	≤ 9 (77%)	NE	NR	NE	NA

¹Independent Review Facility assessment;

²RECIST 1.1; ³modified RECIST; ORR: Objective response rate; DCR: Disease control rate; PFS: Progression free survival; OS: Overall survival; DOR: Duration of response; NR: Not reached; NE: Not estimable; NA: Not available.